The FDA has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for the treatment of adults with type 2 diabetes.
The FDA has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for the treatment of adults with type 2 diabetes.
The FDA has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for the treatment of adults with type 2 diabetes.
The FDA has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for the treatment of adults with type 2 diabetes.
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
